Ratings
0
Nobody has rated this yet. Be the first!
Works
3
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
